Nanobiotix reports Phase 1 NSCLC data for JNJ-1900 showing 79% one-year locoregional control rate

• Nanobiotix reported full-cohort Phase 1 results for JNJ-1900 (NBTXR3) in recurrent, inoperable NSCLC; data were presented at IASLC WCLC 2026.
• Treatment was delivered without dose-limiting toxicities; no severe side effects were tied to JNJ-1900 or the injection procedure.
• Investigators saw signs of meaningful local disease control, supporting use of a lower repeat-radiation dose than patients previously received.
• The study’s dose-escalation and expansion enrollment is complete; additional patient enrollment is planned following the results.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanobiotix SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140200OMX_____CNEWS_EN_GNW9825791_en) on September 14, 2026, and is solely responsible for the information contained therein.